Market Research Industry Reports

Biocon Ltd (BIOCON) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Summary

Biocon Ltd (Biocon) is a biopharmaceutical company that focuses on the research and development of therapies for the treatment of chronic conditions like cancer, diabetes and autoimmune. The company produces a wide range of active pharmaceutical ingredients (APIs), branded formulations; and complex biologics both novels and biosimilars including monoclonal antibodies (MAbs), rh-Insulin and insulin analogs. It also provides research services including discovery, development and manufacturing services for both small and large molecules. Biocon provides research solutions to the biotechnology and pharmaceutical companies worldwide. It has an overseas manufacturing facility at BioXcell, a biotechnology park in Johor, Malaysia. Biocon is headquartered in Bangalore, Karnataka, India.

Biocon Ltd (BIOCON) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

it derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.



List of Tables 5
List of Figures 5
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Biocon Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Biocon Ltd, Medical Devices Deals, 2012 to YTD 2018 11
Biocon Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Biocon Ltd, Pharmaceuticals & Healthcare, Deal Details 14
Asset Purchase 14
Biocon Biologics India to Acquire Biosimilars Business from Biocon 14
Biocon Acquires Pharma Manufacturing Unit from Acacia Life Sciences 15
Venture Financing 16
Syngene May Raise Over USD50 Million in Venture Financing 16
Private Equity 17
Silver Leaf Oak Acquires 10% Stake in Syngene International from Biocon Research for USD62.2 Million 17
IVF Trustee Acquires 10% Stake in Syngene International for USD62 Million 19
GE Equity International Mauritius Completes Acquisition Of 7.69% Stake In Syngene International For US$23 Million 20
Partnerships 22
Mylan Enters Into Licensing Agreement With Biocon For Three Generic Insulin Products 22
Artelo Biosciences Enters into Agreement with Syngene International and Aptus Clinical 23
Syngene International Enters into Agreement with Zumutor Biologics 24
Sandoz International Enters into Agreement with Biocon 25
Biocon Enters into Agreement with Juvenile Diabetes Research Foundation 26
Biocon Enters into Co-Development Agreement with Laboratorios PiSA 27
Saniona Enters into Agreement with Syngene 28
Syngene International Extends R&D Agreement with Bristol-Myers Squibb 29
CytoSorbents Expands Co-Marketing Agreement with Biocon 30
Biocon On The Lookout For Partners To Develop And Market Psoriasis Drug Itolizumab 31
Biocon Plans To Enter Into Co-Development Agreement For Biosimilars 32
Abbott India Enters Into Joint Venture Agreement With Syngene International 33
Licensing Agreements 34
Advaxis Enters Into Licensing Agreement With Biocon For ADXS-HPV 34
Biocon Enters Into Licensing Agreement With CCM Pharma For Insulin Products 36
Biocon Enters Into Option For Licensing Agreement With Bristol-Myers Squibb 37
Biocon Enters into Licensing Agreement with Gilead Sciences 38
Biocon And Quark Pharma Enter Into Agreement To Develop siRNA Based Therapeutics 39
Equity Offering 40
Biocon May Raise up to USD500 Million in Public Offering 40
Syngene International Raises up to USD86 Million in IPO 41
Asset Transactions 43
Biocon Biologics India to Acquire Biosimilars Business from Biocon 43
Biocon Ltd - Key Competitors 44
Biocon Ltd - Key Employees 45
Biocon Ltd - Locations And Subsidiaries 46
Head Office 46
Other Locations & Subsidiaries 46
Joint Venture 47
Recent Developments 48
Strategy And Business Planning 48
Aug 11, 2017: Biocon Announces Incorporation of a Wholly Owned Subsidiary in Malaysia 48
Financial Announcements 49
Jul 26, 2018: Biocon Q1FY19 revenue Rs 1,193 Cr, Up 21%; EBITDA up 25% at Rs 307 Cr; net profit up 47% at Rs 120 Cr 49
Apr 26, 2018: Biocon Q4FY18 Revenue Rs 1,237 Cr, Up 27%; EBITDA Up 30% at Rs 300 Cr; Net Profit Up 2% at Rs 130 Cr[TOPC : Pharma - Biocon Ltd] 52
Oct 26, 2017: Biocon Q2FY18 Revenues at Rs 1019 Crore; EBITDA at Rs 233 Crore; Net Profit at Rs 69 Crore 55
Jul 27, 2017: Biocon Reports Q1FY18 Revenue at Rs 988 Crore; EBITDA at Rs 246 Crore; Net Profit at Rs 81 Crore 58
Apr 27, 2017: Biocon Q4 FY17 Revenue Rs 974 Cr; Net Profit Rs 127 Cr; FY17 Revenue at Rs 4,079 Cr; Net Profit at Rs 612 Cr 62
Jan 24, 2017: Biocon Q3 FY17 Net Profit Up 65% at Rs 171 Crore 65
Legal and Regulatory 68
Jul 04, 2018: Biocons Sterile Drug Product facility Receives EU GMP Certification 68
Jun 23, 2018: Biocons Sterile Drug Product facility Receives EIR from U.S. FDA 69
May 02, 2018: Biocon Regulatory Audit Update 70
Mar 13, 2018: Update On Company Statement On US-FDA Inspection At Biocon Malaysia 71
Feb 21, 2018: Biocon Announces US-FDA Inspection at Malaysian Manufacturing Facility 72
Nov 20, 2017: Biocons Drug product Facility Receives EIR with VAI status, Inspection Closed 73
Sep 18, 2017: Biocons Facility in Vishakhapatnam completes USFDA Inspection with no observations 74
Jul 09, 2017: Biocon provides update on Bangalore Facility 75
Jul 09, 2017: Biocon: Update on Inspection Audits by French health agency 76
May 10, 2017: Biocon statement in response to media reports on USFDA Form 483s for Biocon Limited 77
Other Significant Developments 78
Dec 13, 2017: Biocons Clarification post media reports on Biocon on the FDA list for not paying facility fee 78
Oct 06, 2017: Biocon: No Separate Audit or Observations by Health Canada 79
May 05, 2017: Biocon: Company Statement Media Reports on USFDA 483s 80
Appendix 81
Methodology 81
About GlobalData 81
Contact Us 81
Disclaimer 81

List Of Tables


Biocon Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Biocon Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Biocon Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Biocon Ltd, Medical Devices Deals, 2012 to YTD 2018 11
Biocon Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Biocon Biologics India to Acquire Biosimilars Business from Biocon 14
Biocon Acquires Pharma Manufacturing Unit from Acacia Life Sciences 15
Syngene May Raise Over USD50 Million in Venture Financing 16
Silver Leaf Oak Acquires 10% Stake in Syngene International from Biocon Research for USD62.2 Million 17
IVF Trustee Acquires 10% Stake in Syngene International for USD62 Million 19
GE Equity International Mauritius Completes Acquisition Of 7.69% Stake In Syngene International For US$23 Million 20
Mylan Enters Into Licensing Agreement With Biocon For Three Generic Insulin Products 22
Artelo Biosciences Enters into Agreement with Syngene International and Aptus Clinical 23
Syngene International Enters into Agreement with Zumutor Biologics 24
Sandoz International Enters into Agreement with Biocon 25
Biocon Enters into Agreement with Juvenile Diabetes Research Foundation 26
Biocon Enters into Co-Development Agreement with Laboratorios PiSA 27
Saniona Enters into Agreement with Syngene 28
Syngene International Extends R&D Agreement with Bristol-Myers Squibb 29
CytoSorbents Expands Co-Marketing Agreement with Biocon 30
Biocon On The Lookout For Partners To Develop And Market Psoriasis Drug Itolizumab 31
Biocon Plans To Enter Into Co-Development Agreement For Biosimilars 32
Abbott India Enters Into Joint Venture Agreement With Syngene International 33
Advaxis Enters Into Licensing Agreement With Biocon For ADXS-HPV 34
Biocon Enters Into Licensing Agreement With CCM Pharma For Insulin Products 36
Biocon Enters Into Option For Licensing Agreement With Bristol-Myers Squibb 37
Biocon Enters into Licensing Agreement with Gilead Sciences 38
Biocon And Quark Pharma Enter Into Agreement To Develop siRNA Based Therapeutics 39
Biocon May Raise up to USD500 Million in Public Offering 40
Syngene International Raises up to USD86 Million in IPO 41
Biocon Biologics India to Acquire Biosimilars Business from Biocon 43
Biocon Ltd, Key Competitors 44
Biocon Ltd, Key Employees 45
Biocon Ltd, Subsidiaries 46
Biocon Ltd, Joint Venture 47

List Of Figures


Biocon Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Biocon Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Biocon Ltd, Medical Devices Deals, 2012 to YTD 2018 11

Biocon Ltd (BIOCON) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Biocon Ltd (Biocon) is a biopharmaceutical company that focuses on the research and development of therapies for the treatment of chronic conditions like cancer, diabetes and autoimmune. The company produces

USD 250View Report

Biocon Limited Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Biocon Limited Company Profile is a detailed strategic and analytical report on Biocon Limited. The 2018 version of the report offers detailed insights into the companys strategies, developments, outlook and

USD 200View Report

Biocon Ltd (BIOCON) - Financial and Strategic SWOT Analysis Review

Biocon Ltd (BIOCON) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by it

USD 125View Report

Biocon Ltd (BIOCON) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Biocon Ltd (Biocon) is a global biopharmaceutical company specialized in biopharmaceuticals and research services. The company produces a wide range of active pharmaceutical ingredients (APIs), branded formulations; and complex biologics

USD 250View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 250
  • Site Licence    USD 500
  • Enterprise Wide Licence    USD 750
$ 250

Reports Details

Published Date : Sep 2018
No. of Pages :81
Country :India
Category :Company Profiles
Publisher :GlobalData
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube